Abstract
Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinical trials. Anti- HER-2 therapy among an elderly population was reviewed including approaches for making treatment effective.
Keywords: Anti-HER2 therapy, breast cancer, HER-2/neu, elderly.
Graphical Abstract
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
57